New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation

Ahmed Nasser Abdulhussein , Mohammed Abdulameer Oleiwi

Abstract


Background and purpose: Angiogenesis, regulated by vascular endothelial growth factor receptor 2 (VEGFR-2), has a key role in tumor progression, especially in common cancers, including colorectal and renal cancer. Inhibiting VEGFR-2 is a promising therapeutic approach. This research aimed to design, synthesize, and biologically evaluate new 5-(pyridine-3-yl)-1,3,4-oxadiazole derivatives as potential VEGFR-2 inhibitors.

Experimental approach: A new series of derivatives (AM3-AM6) was synthesized through S-alkylation of 5-(pyridin-3-yl)-1,3,4-oxadiazole-2-thiol and hydrazinolysis reactions, followed by condensation with aldehydes. The compounds were analyzed using FT-IR, ¹H-NMR, and ¹³C-NMR spectroscopy. Molecular modelling studies, including docking (PDB ID: 4ASD), ADMET prediction, and molecular dynamics (MD) simulations, were performed to evaluate binding affinity, pharmacokinetic properties, and complex stability. Cytotoxicity was assessed via MTT assay against HT-29 (colorectal), ACHN (renal), and L929 (normal) cell lines.

Findings/Results: Docking results revealed strong binding to VEGFR-2, with compound AM3 showing the best docking score (∆G = -11.613 kcal/mol). MD simulations confirmed the high stability of the AM3-VEGFR-2 complex with consistent RMSD values and persistent interactions with GLU885 and ASP1046. In vitro, AM4 exhibited a significant cytotoxic effect against HT-29 cells (IC₅₀ = 38.94 µM), compared to sorafenib (IC₅₀ = 9.73), while all compounds were non-toxic toward L929 cells.

Conclusions and implications: In silico and in vitro results demonstrated that the new 5-(pyridine-3-yl)-1,3,4-oxadiazole derivatives possess favorable drug-like properties and selective anti-proliferative activity against colorectal and renal cancer cells. These findings suggest that this scaffold is a valuable starting point for developing novel selective VEGFR-2 inhibitors as anticancer agents.

 


Keywords


Cytotoxicity; 1,3,4-Oxadiazole; Molecular modelling; VEGFR-2.

Full Text:

PDF

References


Oleiwi MA, Zalzala MH, Khudhair AR, Hadi MK, Abdulazeez ZD. Evaluation of the wound-healing activity and apoptotic induction of new quinazolinone derivatives. Al-Rafidain J Med Sci. 2024;6(2):32-36. DOI: 10.54133/ajms.v6i2.640

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. DOI: 10.3322/caac.21820.

Sharma S, Kumar C, Kushwaha H, Jha SK, Chawla S, Sharma A, et al. Advancing anticancer drug development: overcoming challenges and exploring new therapeutic strategies. Ayush J Integr Oncol. 2025;2(1):8-27. DOI: 10.4103/ajio.ajio_3_25.

Lorenc P, Sikorska A, Molenda S, Guzniczak N, Dams-Kozlowska H, Florczak A. Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF/VEGFR pathway. Biomed Pharmacother. 2024;180:117585,1-21. DOI: 10.1016/j.biopha.2024.117585.

Lee C, Kim MJ, Kumar A, Lee HW, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther. 2025;10(1):170,1-40.DOI: 10.1038/s41392-025-02249-0.

Mahaki H, Nobari S, Tanzadehpanah H, Babaeizad A, Kazemzadeh G, Mehrabzadeh M, et al. Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights. Biomed Pharmacother. 2025;186:118023,1-16.DOI: 10.1016/j.biopha.2025.118023.

Liu XJ, Zhao HC, Hou SJ, Zhang HJ, Cheng L, Yuan S, et al. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. Bioorg Chem. 2023;133:106425,1-23.DOI: 10.1016/j.bioorg.2023.106425.

Marques CS, Brandão P, Burke AJ. Targeting vascular endothelial growth factor receptor 2 (VEGFR-2): latest insights on synthetic strategies. Molecules. 2024;29(22):5341,1-49. DOI: 10.3390/molecules29225341.

Khamkar T, Kadam R, Mali SS, Udugade B, Singh S. Recent advances in synthetic approaches for 1, 3, 4-oxadiazole derivatives: a comprehensive review on therapeutic applications. Open Med Chem J. 2025;19(1):e18741045372896,1-16. DOI: 10.2174/0118741045372896250619051210.

Mohamed MFA, Ahmed EA, Alshazly O, Omran OA, Soomro RA, Nafady A. Synthesis, anticancer and anti-inflammatory evaluation of novel quinoxaline-1,3,4-oxadiazole derivatives as EGFR and COX-2 inhibitors. J Mol Struct. 2025;1331:141651,1-12.DOI: 10.1016/j.molstruc.2025.141651.

Tang Z, Hu M, Gan Y, Wen L, Wang Y, Xie Y, et al. Design, synthesis, and evaluation of 1, 3, 4-oxadiazole-based EGFR inhibitors. Bioorg Med Chem Lett. 2025;127:130315,1-8.DOI: 10.1016/j.bmcl.2025.130315.

Mishra SS, Samanta A, Paul A, Maji A, Maity TK. Unveiling the anti-cancer potential of oxadiazole derivatives: a comprehensive exploration of structure-activity relationships and chemico-biological insights. Med Chem. 2025;21(6):445-470. DOI: 10.2174/0115734064329573240823113924.

Lata S, Choudhary L, Bharwal A, Pandit A, Abbot V. A comprehensive review: synthesis and pharmacological activities of 1, 3, 4-oxadiazole hybrid scaffolds. Med Chem. 2025;21(10):1051-1071. DOI: 10.2174/0115734064354700241202174614.

Doddagaddavalli MA, Kalalbandi VKA, Seetharamappa J, Joshi SD. New thiophene-1,3,4-oxadiazole-thiazolidine-2,4-dione hybrids: synthesis, MCF-7 inhibition and binding studies. Bioorg Chem. 2024;143:107003. 1-15.DOI: 10.1016/j.bioorg.2023.107003.

Craig RA, De Vicente J, Estrada AA, Feng JA, Lexa KW, Canet MJ, et al. Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases. J Med Chem. 2024;67(7):5758-5782. DOI: 10.1021/acs.jmedchem.3c02422.

Nath R, Debnath B, Chakraborty A, Khan SA, Maity A, Akhtar MJ. The emerging role of oxadiazole derivatives as VEGFR and EGFR inhibitors in cancer therapy. Bioorg Chem. 2025;166:109140. 1-26.DOI: 10.1016/j.bioorg.2025.109140.

Acar Çevik U, Celik I, Görgülü Ş, Inan Z, Özkay Y, Kaplacıklı Z. New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: synthesis, anticancer evaluation, and docking study. Drug Dev Res. 2024;85(4):e22218. 1-10.DOI: 10.1002/ddr.22218.

Osmaniye D, Haji Ali SJ, Korkut Çelikateş B, Ilgın S, Özkay Y, Kaplancıklı ZA. Investigation of anticancer effects of novel piperidine-oxadiazole and piperidine-triazole derivatives as VEGFR inhibitors and evaluation of their molecular docking-dynamic studies. J Mol Struct. 2024;1316:139012. 1-12.DOI: 10.1016/j.molstruc.2024.139012

Hasan Y, Al-hamashi A. Identification of selisistat derivatives as SIRT1-3 inhibitors by in silico virtual screening. Turk Comput Theor Chem. 2023;8(2):1-11. DOI: 10.33435/tcandtc.1224592

Ali R, Al-Hamashi A. Molecular docking, ADMET, molecular dynamic simulation, synthesis, and preliminary antiproliferative study of 1, 2, 4-thiadiazole derivatives as possible histone deacetylase inhibitors. Trop J Pharm Res. 2024;23(7):1069-1076. DOI: 10.4314/tjpr.v23i7.4.

Hadi MK, Abdulkadir MQ, Oleiwi MA, Ahmed S, Kamms ZD. Synthesis, characterization and preliminary antimicrobial study of some new ether and thioether derivatives of sulfadiazine. Iraqi J Pharm Sci. 2025;34(1):176-184. DOI: 10.31351/vol34iss1pp176-184.

Tawfeeq MF, Qassir AJ. Synthesis, characterization, and antibacterial evaluation of new vanillic acid derivatives. Iraqi J Pharm Sci. 2020;29(2):129-138.DOI: 10.31351/vol29iss2pp129-138.

Chaudhari PJ, Nemade AR, Shirkhedkar AA. Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents. RSC Adv. 2024;14(45):33384-33417. DOI: 10.1039/d4ra05244g.

Fernández-Palacios S, Matamoros E, Morato Rojas I, López Navarrete JT, Ruiz Delgado MC, Vida Y, et al. New insights into acylhydrazones e/z isomerization: an experimental and theoretical approach. Int J Mol Sci. 2023;24(19):14739,1-17. DOI: 10.3390/ijms241914739


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.